---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-25-000104"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:41:12.036340+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics Q3 net loss $2.7M; pauses two trials, extends cash runway to Q1 2027

## Summary
- Net loss $2.7M for Q3 2025 vs $3.5M YoY; cash $7.1M at Sept 30, plus $6.1M raised in Q4 2025.
- INVINCIBLE-4 study paused; plans protocol amendment in Q1 2026 to revise INT230-6 dosing, restart enrollment Q1 2026.
- INVINCIBLE-3 study paused since March 2025 due to funding constraints; 21 patients enrolled, plan to restart with sufficient funding.
- IT-01 study published in eBioMedicine: 75% disease control rate, 11.9 mo median OS; 20% abscopal effects in >40% tumor burden group.
- Capital raises: $7.5M ATM in Q3, $2.1M ATM in Oct, $4.0M registered direct offering in Oct; cash runway extended to Q1 2027.

## SEC filing metadata
- accession: 0001567264-25-000104
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/0001567264-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/intensity-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-25-000104
- JSON: https://secwatch.observer/filing/0001567264-25-000104.json
- Plain text: https://secwatch.observer/filing/0001567264-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.